The Study of Troglitazone Liver Toxicity via Metabolomics and in silico
Troglitazone (TGZ) is a member of thiazolidinedione class of chemicals was developed for the treatment of type 2 diabetes in the late 1990s. TGZ was withdrawn from the market in 2000 due to a number of fatalities due incidence of idiosyncratic liver toxicity. Till date, the mechanism of TGZ-induced liver toxicity is unclear. However, several molecular mechanisms have been proposed to underlie TGZs liver toxicity. Understanding the interactions between these mechanisms could aid drug developers more robustly predict drug-induced liver injury (DILI), a major cause of drug withdrawal.